Favourable responses in Patients with Bulky Neuroendocrine Tumours (NET) - A Personalised Approach Using 90Y-DOTA-Octreotate Sequenced with 177Lu-DOTA-Octreotate Induction Peptide Receptor Chemoradionuclide Therapy (PRCRT)

#1391

Introduction: Bulky disease from NET is an adverse prognostic factor for response to 177Lu-DOTA-octreotate (LuTate) PRCRT. 90Y-DOTA-octreotate (YTate) has more penetrating particulate emissions.

Aim(s): We assessed the efficacy and toxicity of YTate sequenced with LuTate induction in this setting.

Materials and methods: 26 patients (pts) (17 male; 27-74 y.o) completed PRRT using 1-2 YTate cycles sequenced with 2-3 LuTate cycles (median cumulative activity YTate 6.5GBq, LuTate 21GBq) were reviewed. All had at least one lesion >4cm transaxial diameter. 58% had ENETS Grade 2/3, and 73% FDG-avid disease. 7 pts were treated for uncontrolled symptoms, 19 for progressive disease.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Kong G, Callahan J, Hofman M, Pattison D, Akhurst T,

Keywords: PRRT, Y-90,